Bionano Symposium Highlights OGM's Growing Role in Rare Disease Diagnostics

Event summary

  • Bionano Symposium 2026 Day 3 focused on Optical Genome Mapping (OGM) applications in constitutional genetic disorders.
  • Presentations included findings from Japan, India, Brazil, the Netherlands, Turkey, and the United States, with over 1,200 attendees from 73 countries.
  • OGM identified pathogenic variants in 20% of rare disease cases and 12% of previously negative microarray/exome sequencing cases.
  • Bionano’s VIA software is being highlighted as a tool to facilitate OGM data interpretation and standardize workflows.

The big picture

Bionano’s OGM technology addresses a critical need in constitutional genetic disorder diagnostics, where traditional methods often fail to identify the underlying causes. The company's focus on rare diseases, collectively affecting millions, represents a significant market opportunity, but success hinges on demonstrating clinical utility and securing reimbursement. The symposium highlights the growing recognition of OGM's potential, but also underscores the challenges of integrating a novel technology into established clinical workflows.

What we're watching

Adoption Rate
The pace of adoption of OGM in clinical diagnostics will depend on reimbursement models and integration into existing lab workflows, which remains a significant hurdle.
Data Validation
The statistical significance of OGM’s findings in previously negative cases (12%) requires further validation across larger, more diverse cohorts to avoid false positives.
Competitive Landscape
The emergence of alternative structural variant detection technologies could challenge Bionano’s market position, particularly if they offer comparable results at a lower cost.

Related topics

Biotechnology